For sufferers with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) therapy is related to improved medical outcomes in contrast with typical therapies, in line with a examine printed on-line July 14 in JAMA Neurology.
Georgios S. Sioutas, M.D., from the Virginia Commonwealth College Well being System in Richmond, and colleagues carried out a retrospective cohort examine utilizing knowledge from the TriNetX U.S. Collaborative Community between 2005 and 2024. Digital well being data from 67 well being care organizations had been referenced to look at initiation of GLP1-RA remedy inside six months of IIH analysis. The management group included sufferers managed with typical therapies, reminiscent of acetazolamide, topiramate, and dietary counseling.
A complete of 44,373 sufferers with IIH had been recognized; the cohort included 555 GLP-1 RA customers and 555 nonusers, after propensity rating matching. The researchers discovered that use of GLP-1 RAs was related to decrease treatment use, lowered complications, visible disturbances or blindness, and papilledema (threat ratios, 0.53, 0.45, 0.60, and 0.19, respectively). The GLP-1 RA group additionally had a decrease threat of procedures and mortality (threat ratios, 0.44 and 0.36, respectively), however no distinction was seen between the teams in imply physique mass index (BMI) at follow-up. Comparable associations had been seen in sensitivity evaluation stratified by BMI (≥40 versus 2). Larger weight reduction was seen in affiliation with bariatric surgical procedure, however higher outcomes had been seen in affiliation with GLP-1 RA remedy.
“This retrospective multicenter study suggests GLP-1 RAs may benefit IIH management,” the authors write. “However, prospective studies are warranted to validate these findings.”
Extra info:
Georgios S. Sioutas et al, GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension, JAMA Neurology (2025). DOI: 10.1001/jamaneurol.2025.2020
Nancy J. Newman et al, GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a Trial, JAMA Neurology (2025). DOI: 10.1001/jamaneurol.2025.2019
Quotation:
GLP-1 receptor agonists might enhance outcomes in idiopathic intracranial hypertension (2025, July 21)
retrieved 21 July 2025
from https://medicalxpress.com/information/2025-07-glp-receptor-agonists-outcomes-idiopathic.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
